Morgan Stanley Forecasts Strong Price Appreciation for TransMedics Group (NASDAQ:TMDX) Stock

TransMedics Group (NASDAQ:TMDX) had its price target upped by equities researchers at Morgan Stanley from $123.00 to $135.00 in a research note issued on Tuesday,Benzinga reports. The firm currently has an “equal weight” rating on the stock. Morgan Stanley’s price target points to a potential downside of 3.64% from the stock’s current price.

TMDX has been the subject of a number of other research reports. Stifel Nicolaus assumed coverage on TransMedics Group in a report on Thursday, September 4th. They issued a “hold” rating and a $115.00 price target for the company. Evercore ISI began coverage on TransMedics Group in a research note on Tuesday, September 16th. They set an “outperform” rating and a $155.00 target price for the company. Jefferies Financial Group assumed coverage on shares of TransMedics Group in a research note on Monday, October 13th. They issued a “buy” rating and a $145.00 price target for the company. Wall Street Zen upgraded shares of TransMedics Group from a “hold” rating to a “buy” rating in a research note on Saturday, October 18th. Finally, Needham & Company LLC reaffirmed a “buy” rating on shares of TransMedics Group in a research report on Thursday, October 30th. Seven equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $133.00.

TransMedics Group Price Performance

TMDX opened at $140.10 on Tuesday. TransMedics Group has a twelve month low of $55.00 and a twelve month high of $156.00. The firm has a market cap of $4.79 billion, a price-to-earnings ratio of 56.72 and a beta of 2.06. The company has a current ratio of 7.69, a quick ratio of 7.13 and a debt-to-equity ratio of 1.43. The company has a fifty day simple moving average of $124.06 and a 200 day simple moving average of $122.64.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Wednesday, October 29th. The company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.29. The firm had revenue of $143.82 million for the quarter, compared to analyst estimates of $145.33 million. TransMedics Group had a net margin of 16.20% and a return on equity of 31.42%. The firm’s revenue was up 32.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.12 EPS. Equities research analysts expect that TransMedics Group will post 1 EPS for the current fiscal year.

Insider Activity at TransMedics Group

In related news, Director Edward M. Basile sold 4,142 shares of the stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $130.45, for a total value of $540,323.90. Following the completion of the transaction, the director directly owned 2,866 shares of the company’s stock, valued at $373,869.70. This represents a 59.10% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Anil P. Ranganath sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $145.22, for a total value of $435,660.00. Following the completion of the sale, the insider owned 13,955 shares in the company, valued at approximately $2,026,545.10. This represents a 17.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 7.00% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Opal Wealth Advisors LLC bought a new stake in shares of TransMedics Group during the second quarter valued at about $26,000. Whittier Trust Co. of Nevada Inc. increased its stake in TransMedics Group by 981.0% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company’s stock valued at $26,000 after buying an additional 206 shares during the period. Salomon & Ludwin LLC acquired a new stake in shares of TransMedics Group in the 3rd quarter worth approximately $28,000. Harvest Fund Management Co. Ltd acquired a new stake in shares of TransMedics Group in the 3rd quarter worth approximately $29,000. Finally, Smartleaf Asset Management LLC boosted its holdings in shares of TransMedics Group by 44.3% in the first quarter. Smartleaf Asset Management LLC now owns 440 shares of the company’s stock valued at $30,000 after acquiring an additional 135 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.